Abstract
It has long been recognized that the central nervous system (CNS) exhibits only limited capacity for axonal regeneration following injury. It has been proposed that myelin-associated inhibitory molecules are responsible for the nonpermissive nature of the CNS environment to axonal regeneration. Experimental strategies to enhance regeneration by neutralizing these inhibitory molecules are rapidly advancing toward clinical application. It is therefore important that the physiological distribution and functions of these supposed inhibitory molecules should be understood. In this review, we examine the distribution of these inhibitors of neurite outgrowth in relation to the longitudinal polarization of the myelinated axon into the node of Ranvier and associated domains and explore their potential domain specific physiological functions. Potential implications for the therapeutic strategy of neutralizing these inhibitory molecules to promote neural repair are discussed.
Keywords: myelin-associated glycoprotein, oligodendrocyte precursor cells, peripheral nervous system, myelinated axons, TN-R knockout mice
Current Pharmaceutical Design
Title: Physiological Roles of Neurite Outgrowth Inhibitors in Myelinated Axons of the Central Nervous System – Implications for the Therapeutic Neutralization of Neurite Outgrowth Inhibitors
Volume: 13 Issue: 24
Author(s): Quan-Hong Ma, Wu-Lin Yang, Du-Yu Nie, Gavin S. Dawe and Zhi-Cheng Xiao
Affiliation:
Keywords: myelin-associated glycoprotein, oligodendrocyte precursor cells, peripheral nervous system, myelinated axons, TN-R knockout mice
Abstract: It has long been recognized that the central nervous system (CNS) exhibits only limited capacity for axonal regeneration following injury. It has been proposed that myelin-associated inhibitory molecules are responsible for the nonpermissive nature of the CNS environment to axonal regeneration. Experimental strategies to enhance regeneration by neutralizing these inhibitory molecules are rapidly advancing toward clinical application. It is therefore important that the physiological distribution and functions of these supposed inhibitory molecules should be understood. In this review, we examine the distribution of these inhibitors of neurite outgrowth in relation to the longitudinal polarization of the myelinated axon into the node of Ranvier and associated domains and explore their potential domain specific physiological functions. Potential implications for the therapeutic strategy of neutralizing these inhibitory molecules to promote neural repair are discussed.
Export Options
About this article
Cite this article as:
Quan-Hong Ma , Wu-Lin Yang , Du-Yu Nie , Gavin S. Dawe and Zhi-Cheng Xiao , Physiological Roles of Neurite Outgrowth Inhibitors in Myelinated Axons of the Central Nervous System – Implications for the Therapeutic Neutralization of Neurite Outgrowth Inhibitors, Current Pharmaceutical Design 2007; 13 (24) . https://dx.doi.org/10.2174/138161207781368602
DOI https://dx.doi.org/10.2174/138161207781368602 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Emerging Adenoviral Vectors for Stable Correction of Genetic Disorders
Current Gene Therapy New Perspectives in Glioma Immunotherapy
Current Pharmaceutical Design Transferrin and the Transferrin Receptor: Of Magic Bullets and Other Concerns
Inflammation & Allergy - Drug Targets (Discontinued) Dendritic Cells in Esophageal Adenocarcinoma: The Currently Available Information and Possibilities to use Dendritic Cells for Immunotherapeutic Approaches
Current Pharmaceutical Design Cancer Stem Cells and their Management in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Targeted α-Particle Therapy: A Clinical Overview
Current Radiopharmaceuticals Eliminating Ovarian Cancer Stem Cells: A Potential Therapeutic Target for Ovarian Cancer Chemoresistance
Current Protein & Peptide Science Epidermal Growth Factor Receptors: A Functional Perspective
Current Radiopharmaceuticals Molecular Mechanisms of Action of Gas1 and its Possible Therapeutic Applications
Current Signal Transduction Therapy Roles of p75NTR in Maintaining Brain Hemostasis and the Implications for p75NTR-targeted Therapies
Current Alzheimer Research EDITORIAL (Hot Topic: Cancer Chemoresistance and DNA Repair)
Current Medicinal Chemistry Antitumor and Antiviral Activity of Pentacyclic Triterpenes
Mini-Reviews in Organic Chemistry Cruciferous Plants: Phytochemical Toxicity Versus Cancer Chemoprotection
Mini-Reviews in Medicinal Chemistry Targeting Tumor Ubiquitin-Proteasome Pathway with Polyphenols for Chemosensitization
Anti-Cancer Agents in Medicinal Chemistry Translational Gap in Glioma Research
Anti-Cancer Agents in Medicinal Chemistry Nanosized Drug Delivery Systems for Direct Nose to Brain Targeting: A Review
Recent Patents on Drug Delivery & Formulation Ferroptosis: A Trusted Ally in Combating Drug Resistance in Cancer
Current Medicinal Chemistry P-Glycoprotein and Breast Cancer Resistance Protein Affect Disposition of Tandutinib, A Tyrosine Kinase Inhibitor
Drug Metabolism Letters Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas
Current Molecular Medicine Emerging Role of NF-κB in the Pathogenesis of Hepatic Encephalopathy
Current Signal Transduction Therapy